Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10

The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to secrete the cytokine. Intragast...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2000-08, Vol.289 (5483), p.1352-1355
Main Authors: Steidler, Lothar, Hans, Wolfgang, Schotte, Lieven, Neirynck, Sabine, Obermeier, Florian, Falk, Werner, Fiers, Walter, Remaut, Erik
Format: Article
Language:English
Subjects:
Animals
Bacteria
Biological and medical sciences
Biological Transport
Care and treatment
Clinical trials
Colitis
Colitis - immunology
Colitis - pathology
Colitis - prevention & control
Colitis - therapy
Colon
Colon - immunology
Colon - metabolism
Colon - microbiology
Colon - pathology
Dextran Sulfate
Digestive system
Environmental Influences
Etiology
Gastroenterology
Histology
Inflammation
Inflammatory bowel diseases
Inflammatory Bowel Diseases - immunology
Inflammatory Bowel Diseases - pathology
Inflammatory Bowel Diseases - prevention & control
Inflammatory Bowel Diseases - therapy
Interleukin-10
Interleukin-10 - administration & dosage
Interleukin-10 - biosynthesis
Interleukin-10 - genetics
Interleukin-10 - metabolism
Intestinal Mucosa - metabolism
Intestinal Mucosa - pathology
Lactococcus lactis
Lactococcus lactis - genetics
Lactococcus lactis - immunology
Lactococcus lactis - metabolism
Medical research
Medical sciences
Medical treatment
Mice
Pharmacology. Drug treatments
Probiotics - therapeutic use
Recombinant Proteins - administration & dosage
Recombinant Proteins - biosynthesis
Recombinant Proteins - metabolism
Rodents
Ulcerative colitis
Whistles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to secrete the cytokine. Intragastric administration of IL-10-secreting Lactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10-/-mice. This approach may lead to better methods for cost-effective and long-term management of IBD in humans.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.289.5483.1352